Clinical Trial Update: Erlotinib Plus Docetaxel in Treating Patients With Locally Advanced, Metastatic, or Recurrent Head and Neck Cancer [Phase 1, Phase 2]

View source ↗

Summary

Phase 1/Phase 2 clinical trial evaluating the combination of erlotinib and docetaxel in patients with locally advanced, metastatic, or recurrent head and neck c…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Head and Neck Cancer
• Hypopharyngeal Squamous Cell Carcinoma
• Laryngeal Squamous Cell Carcinoma
• Nasopharyngeal Squamous Cell Carcinoma
• Oral Cavity Squamous Cell Carcinoma
• Oropharyngeal Squamous Cell Carcinoma
• Salivary Gland Cancer

Drugs mentioned

• Tarceva (erlotinib)
• Taxotere (docetaxel)

Snippet

Sponsor: National Cancer Institute (NCI) | Conditions: Recurrent Salivary Gland Cancer, Recurrent Squamous Cell Carcinoma of the Hypopharynx | Phase 1, Phase 2 | Status: COMPLETED